相关实验视频

Updated: Jun 6, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

通过药物重新定位来探索肺癌中PDK3抑制的潜在治疗干预措施

Zeba Firdos Khan¹, Aanchal Rathi², Afreen Khan³

¹Department of Biosciences, Faculty of Life Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, 110025, India.

Scientific reports

|November 29, 2024

概括

研究人员确定了FDA批准的药物,巴格洛辛和脱水胆酸,作为pyruvate脱水酶激酶-3 (PDK3) 的潜在抑制剂. 这些化合物通过破坏癌细胞代谢,显示出针对肺癌的前景.

科学领域:

生物化学生物化学
分子生物学分子生物学
计算化学计算化学

背景情况:

甲酸脱酶激酶-3 (PDK3) 通过抑制甲酸脱酶复合体 (PDC) 在调节癌症代谢方面至关重要.
这种抑制将细胞能量生产转移到糖解,支持癌细胞的增殖.

研究的目的:

通过计算药物设计来确定用于肺癌治疗的潜在PDK3抑制剂.
评估FDA批准的化合物是否能够结合和抑制PDK3.

主要方法:

对3839个FDA批准的化合物进行PDK3.3的虚拟查.
分子对接以评估结合亲和力和相互作用.
分子动力学 (MD) 模拟,主要组件分析 (PCA) 和自由能量景观 (FEL) 分析以确认复杂的稳定性和结合模式.

主要成果:

巴格洛辛和脱醇酸对PDK3.3表现出强烈的结合亲和力 (分别为-10.6和-10.5千卡/mol).
MD模拟证实了这些化合物与PDK3.3之间的稳定复合物.
PCA和FEL分析表明药物-PDK3复合物的全球能量最小值是有利的.

结论:

巴格洛辛和脱醇酸被确定为有前途的治疗剂,向肺癌中PDK3.
这些FDA批准的药物代表了进一步临床研究肺癌治疗的潜在候选人.

关键词:

药物发现药物发现美国食品和药物管理局批准的药物.肺癌是一种肺癌.模拟MD的模拟方法皮鲁酸盐脱酶激酶-3酶.虚拟选是一个虚拟的选.

更多相关视频

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...